Form 4: Relay Therapeutics Executive Granted Stock Options

Donald A. Bergstrom, President of R&D at Relay Therapeutics, was granted stock options for 400,000 shares of common stock.

Summary

• Donald A. Bergstrom, President of R&D at Relay Therapeutics, received stock options for 400,000 shares of the company's common stock.
• The options have an exercise price of $4.45 per share.
• The options vest in 16 equal quarterly installments starting after January 10, 2025, contingent on continued service with the company.
• The options expire on January 9, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative surprises or concerns.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If the executive leaves the company before the options fully vest, they may forfeit some or all of the options.

Future Outlook

The stock options will vest over the next four years, subject to the executive's continued employment.

Industry Context

Stock options are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry, similar to companies like Moderna, BioNTech, and Regeneron.
• The vesting schedule of 16 equal quarterly installments is also a common practice to ensure long-term commitment from executives.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, equity, vesting, Relay Therapeutics, RLAY, Donald A. Bergstrom